CJC-1295 mechanism, half-life, and the published corpus — without the bro-science. A founder-operator reading of the GHRH analog literature.
CJC-1295 is one of the two compounds the founder-biohacker stack treats as a single line item. It almost never gets discussed alone. It gets discussed paired with Ipamorelin. That pairing tells you something about how the molecule works — and about how thin the human literature on CJC-1295 itself actually is.
This page is the working reference. Mechanism, half-life, the corpus, the gaps. No dosing. No protocols. Read the brief if you want the issue summaries with citations.
CJC-1295 is a synthetic GHRH analog. GHRH — growth hormone-releasing hormone — is the hypothalamic peptide that tells the pituitary to release growth hormone. CJC-1295 is a modified version of the first 29 amino acids of GHRH, engineered to resist the enzyme that normally clips GHRH apart in plasma within minutes.
Two versions exist in research markets. One is "CJC-1295 with DAC" — DAC stands for Drug Affinity Complex, a maleimide attachment that binds covalently to albumin in circulation. The albumin tether is what produces the multi-day half-life that the compound is known for. The other version, "CJC-1295 without DAC," lacks the maleimide attachment. It is functionally Mod-GRF (1-29) — the bare modified GHRH fragment with a short systemic half-life.
Both versions get sold under the "CJC-1295" name in research-use-only markets, and the conflation is one of the most common sources of confusion in the founder cohort. They are not the same molecule and they do not produce the same pharmacokinetics. When someone says "CJC," ask which one.
CJC-1295 binds the GHRH receptor on pituitary somatotrophs — the cells that produce and release growth hormone. Receptor activation triggers a cAMP-mediated cascade that drives GH synthesis and pulsatile release into circulation. From there, GH acts both directly on tissue and indirectly through hepatic IGF-1 production.
The relevant pharmacology paper is Teichman et al., 2006 in the Journal of Clinical Endocrinology and Metabolism, which characterized the DAC-bound version in healthy human volunteers. That paper showed sustained increases in GH and IGF-1 over multiple days from a single subcutaneous administration. Sackmann-Sala and colleagues extended the mechanistic picture in subsequent work on GHRH analogs and the somatotroph axis.
The pairing logic with Ipamorelin sits one receptor over. Ipamorelin binds the ghrelin receptor (GHSR-1a), a separate GH-axis receptor that responds to a different endogenous signal. Stimulating both receptors at once produces a larger and more pulsatile GH release in animal work than stimulating either alone. This is why the forums treat the two as a unit. The published human work on the combination is sparse; most of the rationale is animal pharmacology and inference from the single-agent papers.
Worth naming clearly: CJC-1295 does not "give you growth hormone." It signals upstream of the pituitary. If the pituitary cannot produce GH — Sheehan's, surgery, severe deficiency — the compound has nothing to act on.
This is where the with-DAC versus without-DAC split matters most.
CJC-1295 with DAC has a reported half-life on the order of 5 to 8 days in the human pharmacokinetic work. The albumin tether is the entire reason. Free GHRH is cleaved by dipeptidyl peptidase-IV in plasma within minutes; the albumin-bound version is shielded from that protease and circulates as a depot.
CJC-1295 without DAC — Mod-GRF (1-29) — has a half-life closer to 30 minutes. The "modified" GHRH backbone resists DPP-IV more effectively than native GHRH, but without the albumin tether, plasma clearance is fast.
Route in published work is subcutaneous injection. Both versions. Other routes appear in community discussion but published support for them is thin to absent.
The half-life difference explains the protocol arguments forum users have. With-DAC produces a sustained elevation that does not mimic natural pulsatile GH secretion. Without-DAC, paired with a ghrelin-receptor agonist, produces shorter pulses that more closely track the endogenous pattern. Both arguments have a mechanistic basis. Neither has been settled in human outcomes work.
The CJC-1295 human corpus is small. Tier 3 in our framework — mechanistic and pharmacokinetic, with the Teichman paper as the anchor.
What the published work establishes:
What the published work does not establish:
This is the gap between literature and practice. The forum discourse is years deeper than the published evidence base on outcomes. Operators running CJC are running on inferred mechanism and N=1.
Forum and N=1 reports across the founder-biohacker community converge on a few patterns.
Sleep depth changes are the most commonly reported subjective effect within the first two weeks. Users describe deeper slow-wave sleep and longer time to wake. Whether this reflects GH pulse architecture or placebo is not separable from N=1.
Skin and connective tissue changes — water retention, sometimes joint discomfort, sometimes a reported tightening of skin — show up in the multi-week window. These are consistent with GH-axis activation but are subjective and unmeasured.
Body composition reports are noisier. Some users report fat loss without lean mass change; others report no measurable change. Reports tend to converge on "this is a GH-axis amplifier, not a body recomp drug on its own."
PIP (post-injection pain) reports vary by source vendor and reconstitution practice. Reports of variability are themselves a signal about the RUO supply chain.
The list is long.
We do not have a randomized human trial of either version against a body composition or recovery endpoint. We do not have head-to-head data on with-DAC versus without-DAC in humans. We do not have long-term safety data at the doses the cohort uses, and we do not have data on what happens to the GH axis after extended administration is stopped.
We do not know whether the multi-day elevation produced by the DAC version is preferable to, equivalent to, or worse than the pulsatile elevation produced by short-acting protocols. There is a real biological argument that pulsatility matters for downstream signaling. There is no published human work that settles it.
We do not have clean comparative data on the CJC-plus-Ipamorelin combination versus either compound alone. Most of the combination rationale is animal pharmacology and forum convergence.
Issue 1 of The Compound is the GH-axis primer for founder-operators — the same axis CJC-1295 acts on. The newsletter handles dosing summaries from the cited literature, vendor signal, and stack synthesis at the email-gate tier. The public archive handles mechanism and the corpus state — this page.
For readers thinking about CJC in the context of GLP-1 use — where lean mass preservation under caloric deficit is the operator concern — Sermorelin and Tesamorelin are closer to that question and have more published outcomes work behind them.
The Peptide Stack Map is the lead magnet on this page. Fourteen compounds, one page each, mechanism through literature. It's the working reference the cohort uses to assemble the picture before reading any single stack post.
For research use only. Not medical advice. Nothing on this page is a recommendation to administer, prescribe, or self-administer any compound.
FTC disclosure: The operator who publishes The Compound also owns heroxbio.com, an RUO peptide vendor. Full disclosure on the About page.
Subscribe to The Compound — the Sunday briefing on peptides for founder-operators.
[Subscribe — get the Peptide Stack Map]
14 compounds, half-lives, and the literature — one PDF.
Download the PDF →